Literature DB >> 32234898

Stereotactic Body Radiotherapy for Pulmonary Oligometastases from Esophageal Cancer: Results and Prognostic Factors.

Takaya Yamamoto1, Yuzuru Niibe2,3, Yasuo Matsumoto4, Yasuhiro Dekura5, Ryoong-Jin Oh6, Hideomi Yamashita7, Hisao Kakuhara8, Masahiko Aoki9, Keiichi Jingu10.   

Abstract

BACKGROUND/AIM: The aim of this multi-center retrospective study was to investigate the results of stereotactic body radiotherapy (SBRT) for pulmonary oligometastases from esophageal cancer. PATIENTS AND METHODS: Oligometastases from the esophagus were identified from a dataset of a Japanese survey. The Kaplan-Meier method and Cox regression were applied to perform analyses.
RESULTS: A total of 114 patients with 132 pulmonary oligometastases were collected. The 3-year local control rate, freedom from further metastasis (FFFM) rate and overall survival (OS) rate were 70.2%, 25.3% and 37.5%, respectively. Performance status (PS) (PS 1 vs. PS 0, p<0.01), disease-free interval (p=0.03) and history of local therapy for metastasis (p=0.01) had significant relationships with FFFM and only PS was an independent prognostic factor for OS (PS 1 vs. PS 0, p=0.02; PS 2-3 vs. PS 0, p=0.04).
CONCLUSION: SBRT for pulmonary oligometastases from esophageal cancer provided good local control and survival. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Stereotactic body radiotherapy (SBRT); esophageal cancer; oligo-recurrence; oligometastases; prognostic factor

Mesh:

Year:  2020        PMID: 32234898     DOI: 10.21873/anticanres.14164

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  1 in total

Review 1.  Current Evidence for Stereotactic Body Radiotherapy in Lung Metastases.

Authors:  Enrique Gutiérrez; Irving Sánchez; Omar Díaz; Adrián Valles; Ricardo Balderrama; Jesús Fuentes; Brenda Lara; Cipatli Olimón; Víctor Ruiz; José Rodríguez; Luis H Bayardo; Matthew Chan; Conrad J Villafuerte; Jerusha Padayachee; Alexander Sun
Journal:  Curr Oncol       Date:  2021-07-15       Impact factor: 3.677

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.